European countries in the race to attract successful biopharma investment: Winners and laggers

European countries in the race to attract successful biopharma investment: Winners and laggers

The post-coronavirus era will open myriad opportunities for the biopharma industry. However, the extent to which each country will take advantage of this promising new scenario will largely depend on its position in a few key areas. Here, we offer an overview of the European countries that are winni...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug discovery today 2021-10, Vol.26 (10), p.2209-2213
Hauptverfasser: March-Chordà, Isidre, Yagüe-Perales, Rosa M.
Format: Artikel
Sprache:eng
Schlagworte:
Biopharma
Europe
Investment
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2213
container_issue 10
container_start_page 2209
container_title Drug discovery today
container_volume 26
creator March-Chordà, Isidre
Yagüe-Perales, Rosa M.
description The post-coronavirus era will open myriad opportunities for the biopharma industry. However, the extent to which each country will take advantage of this promising new scenario will largely depend on its position in a few key areas. Here, we offer an overview of the European countries that are winning and those that are lagging behind in the race to attract the greatest investment in this industry and to attain the highest rate of successful new ventures. Our results highlight the vital importance of a sound, active funding base, especially in terms of venture capital. Our findings also suggests that general scientific foundations are not enough to secure an advantage in new venture formation.
doi_str_mv 10.1016/j.drudis.2021.04.001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2511896636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644621001690</els_id><sourcerecordid>2511896636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-6b8b087c3a7f96a567f2510a02d17c34f4d074d46e90182a9c7be2472cf01cc13</originalsourceid><addsrcrecordid>eNp9kMtKxTAQhoMoXo6-gUiWblpza9q6EESOFxDcKO4MaTLVHNr0mKSCb2_kqEtX8zN8M5N8CB1TUlJC5dmqtGG2LpaMMFoSURJCt9A-beqmqBrOtnPmVVtIIeQeOohxlQHWVnIX7XHe8Ja1dB-9LOcwrUF7bKbZp-AgYudxegMctAGcJqxTyjHhOBsDMfbzgDs3rd90GHVmPyCmEXw6x8_OewgRa2_xoF9fcz5EO70eIhz91AV6ul4-Xt0W9w83d1eX94XhVZ0K2TUdaWrDdd23Uley7llFiSbM0twVvbCkFlZIaAltmG5N3QETNTM9ocZQvkCnm73rML3P-UVqdNHAMGgP0xxV3kabVkouMyo2qAlTjAF6tQ5u1OFTUaK-zaqV2phV32YVESqLy2MnPxfmbgT7N_SrMgMXGwDyPz8cBBWNA2_AugAmKTu5_y98AXKtjKM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2511896636</pqid></control><display><type>article</type><title>European countries in the race to attract successful biopharma investment: Winners and laggers</title><source>Elsevier ScienceDirect Journals</source><creator>March-Chordà, Isidre ; Yagüe-Perales, Rosa M.</creator><creatorcontrib>March-Chordà, Isidre ; Yagüe-Perales, Rosa M.</creatorcontrib><description>The post-coronavirus era will open myriad opportunities for the biopharma industry. However, the extent to which each country will take advantage of this promising new scenario will largely depend on its position in a few key areas. Here, we offer an overview of the European countries that are winning and those that are lagging behind in the race to attract the greatest investment in this industry and to attain the highest rate of successful new ventures. Our results highlight the vital importance of a sound, active funding base, especially in terms of venture capital. Our findings also suggests that general scientific foundations are not enough to secure an advantage in new venture formation.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2021.04.001</identifier><identifier>PMID: 33839291</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biopharma ; Europe ; Investment</subject><ispartof>Drug discovery today, 2021-10, Vol.26 (10), p.2209-2213</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-6b8b087c3a7f96a567f2510a02d17c34f4d074d46e90182a9c7be2472cf01cc13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1359644621001690$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33839291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>March-Chordà, Isidre</creatorcontrib><creatorcontrib>Yagüe-Perales, Rosa M.</creatorcontrib><title>European countries in the race to attract successful biopharma investment: Winners and laggers</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>The post-coronavirus era will open myriad opportunities for the biopharma industry. However, the extent to which each country will take advantage of this promising new scenario will largely depend on its position in a few key areas. Here, we offer an overview of the European countries that are winning and those that are lagging behind in the race to attract the greatest investment in this industry and to attain the highest rate of successful new ventures. Our results highlight the vital importance of a sound, active funding base, especially in terms of venture capital. Our findings also suggests that general scientific foundations are not enough to secure an advantage in new venture formation.</description><subject>Biopharma</subject><subject>Europe</subject><subject>Investment</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKxTAQhoMoXo6-gUiWblpza9q6EESOFxDcKO4MaTLVHNr0mKSCb2_kqEtX8zN8M5N8CB1TUlJC5dmqtGG2LpaMMFoSURJCt9A-beqmqBrOtnPmVVtIIeQeOohxlQHWVnIX7XHe8Ja1dB-9LOcwrUF7bKbZp-AgYudxegMctAGcJqxTyjHhOBsDMfbzgDs3rd90GHVmPyCmEXw6x8_OewgRa2_xoF9fcz5EO70eIhz91AV6ul4-Xt0W9w83d1eX94XhVZ0K2TUdaWrDdd23Uley7llFiSbM0twVvbCkFlZIaAltmG5N3QETNTM9ocZQvkCnm73rML3P-UVqdNHAMGgP0xxV3kabVkouMyo2qAlTjAF6tQ5u1OFTUaK-zaqV2phV32YVESqLy2MnPxfmbgT7N_SrMgMXGwDyPz8cBBWNA2_AugAmKTu5_y98AXKtjKM</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>March-Chordà, Isidre</creator><creator>Yagüe-Perales, Rosa M.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20211001</creationdate><title>European countries in the race to attract successful biopharma investment: Winners and laggers</title><author>March-Chordà, Isidre ; Yagüe-Perales, Rosa M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-6b8b087c3a7f96a567f2510a02d17c34f4d074d46e90182a9c7be2472cf01cc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biopharma</topic><topic>Europe</topic><topic>Investment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>March-Chordà, Isidre</creatorcontrib><creatorcontrib>Yagüe-Perales, Rosa M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>March-Chordà, Isidre</au><au>Yagüe-Perales, Rosa M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>European countries in the race to attract successful biopharma investment: Winners and laggers</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>26</volume><issue>10</issue><spage>2209</spage><epage>2213</epage><pages>2209-2213</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>The post-coronavirus era will open myriad opportunities for the biopharma industry. However, the extent to which each country will take advantage of this promising new scenario will largely depend on its position in a few key areas. Here, we offer an overview of the European countries that are winning and those that are lagging behind in the race to attract the greatest investment in this industry and to attain the highest rate of successful new ventures. Our results highlight the vital importance of a sound, active funding base, especially in terms of venture capital. Our findings also suggests that general scientific foundations are not enough to secure an advantage in new venture formation.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33839291</pmid><doi>10.1016/j.drudis.2021.04.001</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1359-6446
ispartof Drug discovery today, 2021-10, Vol.26 (10), p.2209-2213
issn 1359-6446
1878-5832
language eng
recordid cdi_proquest_miscellaneous_2511896636
source Elsevier ScienceDirect Journals
subjects Biopharma
Europe
Investment
title European countries in the race to attract successful biopharma investment: Winners and laggers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T14%3A34%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=European%20countries%20in%20the%20race%20to%20attract%20successful%20biopharma%20investment:%20Winners%20and%20laggers&rft.jtitle=Drug%20discovery%20today&rft.au=March-Chord%C3%A0,%20Isidre&rft.date=2021-10-01&rft.volume=26&rft.issue=10&rft.spage=2209&rft.epage=2213&rft.pages=2209-2213&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2021.04.001&rft_dat=%3Cproquest_cross%3E2511896636%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2511896636&rft_id=info:pmid/33839291&rft_els_id=S1359644621001690&rfr_iscdi=true